You have been chosen to receive this valuable information.
 
Waters: The Science of What's Possible

Learn more about Medimmune’s success developing an ACQUITY QDa-based MAM method

 
MedImmune, a member of the AstraZeneca Group, recently shared their success in developing a GMP validated peptide-based multi-attribute monitoring method (MAM) to streamline product and process development, one that can be easily deployed across multiple locations for global quality control and release testing.
Dr. Weichen Xu

Dr. Weichen Xu
Medimmune, A member of the AstraZeneca Group

In this presentation, originally given at ASMS 2017, Dr. Weichen Xu from MedImmune discusses the rationale for implementing a peptide-based MAM method, and presents data that underscores why the Waters ACQUITY QDa mass detector operated under the compliant-ready software, Empower, was chosen for this method.

View presentation recording

You can also read about their work in more detail in their recent mAbs publication, "A Quadrupole Dalton-based multi-attribute method for product characterization, process development, and quality control of therapeutic proteins".

Read article →
Waters Blog  |  Contact Waters

©2017 Waters Corporation. Waters and The Science of What's Possible are registered trademarks of Waters Corporation.
Message above is a paid advertisement. Content is provided by the sponsor. You received this email because you are a customer of BioPharm International, a UBM publication. You are on the mailing list as %%emailaddress%%.